138 results on '"Lee, Yong Joon"'
Search Results
2. Analysis of major defects that are repeatedly derived from ISMS-P
3. Supplementary Figures S1-11 from CEACAM1 Marks Highly Suppressive Intratumoral Regulatory T Cells for Targeted Depletion Therapy
4. Supplementary Tables S1-7 from CEACAM1 Marks Highly Suppressive Intratumoral Regulatory T Cells for Targeted Depletion Therapy
5. Supplementary Figures S1-11 from CEACAM1 Marks Highly Suppressive Intratumoral Regulatory T Cells for Targeted Depletion Therapy
6. Supplementary Tables S1-7 from CEACAM1 Marks Highly Suppressive Intratumoral Regulatory T Cells for Targeted Depletion Therapy
7. Predictive value of plaque characteristics for identification of lesions causing ischemia
8. TCTAP C-215 MitraClip Single-Leaflet Detachment and Consequent Migration in Atrial Functional Mitral Regurgitation
9. Continuous Renal Replacement Therapy and Extracorporeal Membrane Oxygenation in Patients with Cardiogenic Shock: A Multicenter Observational Study: Results from the RESCUE Registry
10. Comparison of Intracardiac Echocardiography Versus Transesophageal Echocardiography for Guidance During Transcatheter Aortic Valve Replacement
11. Clinical Significance of Prognostic Nutrition Index in Patients with Crohn’s Disease after Primary Bowel Resection
12. A Study on the Measuring Methods of Website Security Risk Rate
13. Moderate‐intensity statin with ezetimibe combination therapy versus high‐intensity statin monotherapy in patients with metabolic syndrome and atherosclerotic cardiovascular disease: A post‐hoc analysis of the RACING trial
14. Effect of moderate-intensity statin with ezetimibe combination vs. high-intensity statin therapy according to sex in patients with atherosclerosis
15. Combination therapy with moderate-intensity atorvastatin and ezetimibe versus high-intensity atorvastatin monotherapy in patients treated with percutaneous coronary intervention in practice: assessing RACING generalizability
16. Moderate-intensity statin plus ezetimibe vs high-intensity statin according to baseline LDL-C in the treatment of atherosclerotic cardiovascular disease: A post-hoc analysis of the RACING randomized trial
17. Rosuvastatin versus atorvastatin treatment in adults with coronary artery disease: secondary analysis of the randomised LODESTAR trial
18. TCT-184 Treatment of Side Branch Restenosis After 1-Stent Crossover Stenting for Left Main Bifurcation Lesions
19. Treat-to-target versus high-intensity statin treatment in patients with or without diabetes mellitus: a pre-specified analysis from the LODESTAR trial
20. Efficacy of Percutaneous Coronary Intervention With Synergy Stents in Patients Aged ≥75 Years: 1-Year Clinical Outcomes from the Synergy Elderly Registry
21. Postchemoradiation magnetic resonance imaging circumferential resection margin predicts treatment failure after multidisciplinary directed sphincter preservation in low rectal cancer
22. A Study on the Measuring Methods of Websites Security Risk Rate
23. A study on technology protection measures according to the introduction of the cloud business environment for defense companies
24. Design and implementation of control support intelligence for the enhancement of efficiency in the Security Operations Center (SOC)
25. Treating Coronary Artery Disease With Treat-to-Target or High-Intensity Statin—Reply
26. Design and Implementation of IoT Gateway with MQTT and IEC 61850 MMS Protocol
27. Sex Differences in Outcomes of Ticagrelor Therapy With or Without Aspirin After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome: A Post Hoc Secondary Analysis of the TICO Randomized Clinical Trial
28. Perioperative Antiplatelet Strategy in Patients Undergoing Noncardiac Surgery Within One Year After Percutaneous Coronary Intervention
29. Supplementary Figures S1-11 from CEACAM1 Marks Highly Suppressive Intratumoral Regulatory T Cells for Targeted Depletion Therapy
30. Data from CEACAM1 Marks Highly Suppressive Intratumoral Regulatory T Cells for Targeted Depletion Therapy
31. CEACAM marks intratumoral Tregs that exhibited highly suppressive and activated phenotypes
32. Supplementary Figures S1-11 from CEACAM1 Marks Highly Suppressive Intratumoral Regulatory T Cells for Targeted Depletion Therapy
33. Supplementary Tables S1-7 from CEACAM1 Marks Highly Suppressive Intratumoral Regulatory T Cells for Targeted Depletion Therapy
34. Supplementary Tables S1-7 from CEACAM1 Marks Highly Suppressive Intratumoral Regulatory T Cells for Targeted Depletion Therapy
35. A Study on the APT Attack Scenario Verification System
36. Supplementary Figures S1-11 from CEACAM1 Marks Highly Suppressive Intratumoral Regulatory T Cells for Targeted Depletion Therapy
37. Efficacy and safety of moderate-intensity statin with ezetimibe combination therapy in patients after percutaneous coronary intervention: a post-hoc analysis of the RACING trial
38. Body mass index affecting ticagrelor monotherapy vs. ticagrelor with aspirin in patients with acute coronary syndrome: A pre-specified sub-analysis of the TICO randomized trial
39. Stent expansion evaluated by optical coherence tomography and subsequent outcomes
40. Does Age Matter After Successful Left Atrial Appendage Closure?
41. CEACAM1 marks highly suppressive intratumoral regulatory T cells for targeted depletion therapy
42. Assessment of fractional flow reserve in intermediate coronary stenosis using optical coherence tomography-based machine learning
43. Efficacy and Safety of Moderate-Intensity Statin with Ezetimibe Combination Therapy in Patients after Percutaneous Coronary Intervention Results from the RACING Trial
44. Intravascular Ultrasound-Guided Percutaneous Coronary Intervention
45. Moderate-intensity statin with ezetimibe vs. high-intensity statin in patients with diabetes and atherosclerotic cardiovascular disease in the RACING trial
46. Prediction-based Protection of Privacy Areas in Input Images
47. Long coverage with drug-eluting stents is superior to spot coverage for long femoropopliteal artery disease: PARADE II study
48. A Haze Elimination Method Based on Hierarchical Noise Reduction
49. Dapagliflozin attenuates diabetes-induced diastolic dysfunction and cardiac fibrosis by regulating SGK1 signaling
50. Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.